deaths (OS)progression or deaths (PFS)RFS/DFS

hepatocell cancer (HCC) hepatocell cancer (HCC)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -1.0better0.35.051 %-

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 ---

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
durvalumab plus tremelimumab vs. sorafenib 1 1.0better0.35.0100 %1.0better0.35.091 %-

mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)